Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

December 31, 2015

Conditions
Infectious DiseaseBacterial Infections
Interventions
DRUG

P128-0.1 mg

P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.

DRUG

P128-0.3 mg

P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.

DRUG

P128-1.0 mg

P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.

DRUG

Placebo

Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D

Trial Locations (1)

Unknown

National University Hospital, Singapore

All Listed Sponsors
lead

GangaGen, Inc.

INDUSTRY

NCT01746654 - Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients | Biotech Hunter | Biotech Hunter